Core Insights - The total scale of China's biomanufacturing industry has reached 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The annual output value of both food and pharmaceutical biomanufacturing segments exceeds 400 billion yuan [1] - China has established a number of national key laboratories and industrial innovation platforms, with over 20% of global research papers and patent applications originating from the country [1] Group 1 - The biomanufacturing sector is recognized as a crucial form of material production for the future and is expected to be a core driver of the Fourth Industrial Revolution [1] - Traditional bioproducts such as vitamins, amino acids, and antibiotics continue to reduce costs and enhance efficiency, maintaining a global competitive edge [1] - Emerging products like hyaluronic acid and glucosamine are improving in quality, steadily increasing their global market share [1] Group 2 - The conference emphasized the need to strengthen technological research and innovation to address fundamental scientific issues and major engineering bottlenecks in the biomanufacturing industry [2] - It highlighted the importance of collaboration among industry, academia, and research institutions to create a synergistic development model [2] - The conference released several lists, including the first batch of high-performance bioreactor innovation task units and notable biomanufacturing products [2]

企业出海与资本市场对接成效显著。药捷安康、维立志博、果下科技、正力新能等一批独角兽瞪羚企业 成功登陆港交所，凭借全球化布局在港股市场表现强劲；联盟组织企业赴澳大利亚、新加坡开展海外考 察，并参与中国国际供应链促进博览会，为企业搭建全球创新网络融入通道。 资本赋能方面，联盟整合金融资源，举办"新经济、新战略、新投资"等多场投融资对接活动，吸引35家 优质企业与15家顶级投资机构面对面洽谈；与国新基金、江苏省战略母基金等合作开展线上对接，为50 余家高潜力企业提供专属展示平台。 2026年是我国"十五五"规划的开局之年。林倩表示，联盟将紧密对接服务国家"十五五"规划重点方向， 布局未来产业领域培育活动，助力江苏在人工智能、生物制造、商业航天、新材料、低空经济等新赛道 上抢占先机。"2026年我们将重磅推出'科创市集'数字化平台，破解信息不对称难题，提升创新要素匹 配精准度，并与'走进标杆企业''投融资对接''Boss私董会'等品牌活动形成联动，构建线上线下 （300959）融合的服务新模式。" 江南时报讯推动一批企业登陆港交所，共建马来西亚产业园，深化南京都市圈创新生态合作……2025 年，江苏省独角兽瞪羚企业联 ...

2025年A股市场表现延续了2024年的势头，新股数量增加，而融资金额激增，这主要由于得到新"国九 条"及资本市场"1+N"系列政策的支持。来自能源及资源和科技公司的新股推动了新股融资额的大幅增 长。 德勤中国资本市场服务部华东区上市业务合伙人胡科表示，2025年A股新股市场表现更胜2024年，以新 股融资额计，上海证券交易所仍将保持全球第五大证券交易所的排名。持续推进的改革为A股新股发行 在2026年继续升温奠定基础，预计其表现将比2025年更加出色。来自人工智能、新能源、高端制造、商 业航天、量子技术和生物制造等领域的企业，在A股市场上市和融资时将获得更大优势。 2025年香港IPO市场强劲反弹，预计2025年香港将完成114只新股上市，融资约2863亿港元。2024年香 港市场仅有70只新股，融资875亿港元。2025年新股数量将增加63%，融资金额将增长两倍多。 新华财经上海12月18日电（记者高少华）德勤中国资本市场服务部18日发布报告显示，截至2025年12月 31日，预计中国内地A股市场将有114家公司上市，融资额为1296亿元人民币。 2024年则有100家公司上市，融资额为668亿元人民币。 ...

（原标题：总金额超1109亿元项目落户武汉 投资涵盖人工智能等多个新兴产业） 经济观察网现场获悉，本次大会共签约产业项目160个，签约金额1109.7亿元，其中工业项目69个，签 约金额669.9亿元，服务业项目91个，签约金额439.8亿元。上台项目48个，签约金额616.2亿元。城市更 新类项目8个，金额120.4亿元。 此外，大会还举办了以人工智能、生物制造、数字经济及城市更新发展为主题的四场专题对接活动，为 加快建设国家中心城市、全力打造"五个中心"、全面建设现代化大武汉注入全新动能。 经济观察网 程久龙 12月18日，经济观察网从"投资武汉 共赢未来"2025年度武汉投资促进大会获悉，本 次大会共邀请世界500强企业代表、大型跨国公司代表、科技创新型企业代表，其他知名企业及商协会 代表等约240人参加，畅叙合作、共谋发展。现场共签约产业项目160个，签约金额1109.7亿元，涵盖人 工智能、新一代信息技术、大健康和生物制造、数字经济、光电子信息、智能网联汽车、新能源、新材 料、高端装备制造等多个产业领域。 武汉市委副书记、代市长熊征宇在大会致辞中表示："当前，武汉日益成为创新发展热土，投资兴业的 高 ...

Core Insights - The "14th Five-Year Plan" emphasizes the strategic development of six future industries, including quantum technology, biomanufacturing, hydrogen energy, and nuclear fusion energy, with a focus on transitioning from laboratory research to real-world applications [1][3] Group 1: Industry Development - A compact fusion energy experimental device (BEST) has entered the assembly phase, aiming for commercial application of fusion energy during the "14th Five-Year Plan" [3] - Significant breakthroughs in core technologies have been achieved, with several quantum sensors developed and applied in precision equipment across various fields [5] - The "artificial ocean carbon cycle system" in Shenzhen has operated stably for over 500 hours in real seawater, achieving over 70% CO2 capture efficiency, converting seawater CO2 into green raw materials for plastic production [7] Group 2: Market Potential - The market for embodied intelligence is expected to exceed 5 billion yuan by 2025, while the brain-computer interface market is projected to surpass 3.8 billion yuan, and the biomanufacturing industry is anticipated to approach 1 trillion yuan in total scale [11] Group 3: Policy and Support - The government will continue to strengthen policy support, focusing on the core tracks of the six future industries, creating development clusters, and nurturing specialized and innovative enterprises to form new trillion-yuan industry tracks [12]

会上，市科创局、市商务局、市住房和城市更新局分别围绕打造国家科技创新中心、打造国际消费中心城市、推动城市更新作主题推 介。 联影集团董事长薛敏、绿城中国集团执行总裁赵晖、安波福集团电气分配系统事业部副总裁兼中国区总裁祁松、千寻智能（杭州）科 技有限公司联合创始人兼首席执行官韩峰涛、星巴克企业管理（中国）有限公司副总裁周海冰、北京瑞莱智慧科技有限公司首席执行官田 天现场发言。零一万物首席执行官、创新工厂、创新奇智董事长李开复，蔚来创始人、董事长、首席执行官李斌作视频发言。 盛阅春在会见时对嘉宾们来汉表示欢迎，对广大企业为武汉发展作出的贡献表示感谢。他说，武汉是一座动能澎湃的创新之城、实力 雄厚的产业之城、链接全球的枢纽之城、钟灵毓秀的宜居之城，近年来城市地位不断上升，功能定位日益拓展，多重战略机遇叠加，进入 城市能级跃升期、优势转化加速期、转型发展关键期、区域协同发力期。当前，我们正深入学习贯彻党的二十届四中全会精神和习近平总 书记考察湖北重要讲话精神，认真落实省委、省政府部署要求，加快建设国家中心城市，全力打造"五个中心"，全面建设现代化大武汉。 诚邀各位企业家做武汉高质量发展的"城市合伙人"，在科技创新、产 ...

中国电子信息产业发展研究院（以下简称"赛迪研究院"）18日发布《2026年我国未来产业发展形势展 望》，预计2026年我国未来产业发展将迎来重要转折点，多赛道有望实现从技术突破到产业化落地的关 键跨越。 （文章来源：新华财经） 赛迪研究院未来产业研究中心副所长李艺铭表示，2026年，随着"十五五"规划开局，未来产业将加速构 建投入与风险分担机制，多赛道步入产业化关键阶段，科技创新和产业创新深度融合，场景大规模开放 应用有望加速打通技术到产业的路径。 报告指出，2026年我国未来产业发展将迎来重要转折点，多赛道有望实现从技术突破到产业化落地的关 键跨越。如，量子科技逐步从实验室走向特定场景应用，在金融风控、药物研发等领域开展试点示范； 生物制造技术路线持续成熟，在医药研发、农业育种等领域的应用深度不断拓展；可控核聚变进入工程 可行性验证关键阶段，商业化落地加速。这种多技术群协同突破、交叉融合的发展态势，将推动未来产 业从单点创新迈向系统突破，为经济高质量发展注入新动能。 2026年，场景大规模开放应用有望加速打通技术到产业的路径。国家将着力构建"技术突破－场景验证 －产业应用－体系升级"的闭环发展模式，分批次推 ...

Core Insights - The article emphasizes the strategic importance of biomanufacturing, which is projected to create a $30 trillion market, comparable to the significance of chip manufacturing [3] - Biomanufacturing is not merely a replacement for traditional chemical processes but a transformative engine that redefines the underlying logic of industries, impacting the entire supply chain from raw materials to end products [3][4] Company Overview - Jia Bi You has been proactive in the biomanufacturing sector, establishing a robust business model that has evolved significantly since its listing on the STAR Market six years ago [4] - The company reported a revenue increase from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate of 12.2% [4] Market Positioning - The implementation of new national standards for infant formula in February 2023 has created a favorable market environment for Jia Bi You, allowing it to efficiently release production capacity [10] - The expiration of DSM's core patents has enabled Jia Bi You to penetrate international markets and establish stable partnerships with major companies like Nestlé and Danone [12] Strategic Growth - Jia Bi You's revenue structure has diversified, with the human nutrition segment's share decreasing from over 95% to around 80%, while the health sector now contributes nearly 20% [13] - The company maintains a high R&D investment rate of 8%-10%, which has supported its innovation and technological advancements [15] Technological Innovation - The company has developed a comprehensive technology system based on synthetic biology, which includes bioinformatics, AI, and other interdisciplinary fields [15][16] - Jia Bi You aims to leverage AI to enhance its research and application processes, creating a specialized biological database to optimize product development and personalized nutrition solutions [18][19] International Expansion - Jia Bi You's international revenue share has increased from less than 10% to nearly 40%, with products now available in over 30 countries [24] - The company adopts a flexible internationalization strategy, focusing on technology cooperation and customized supply rather than aggressive expansion [25] ESG Commitment - Jia Bi You places significant emphasis on ESG practices, having initiated social responsibility reports since 2019 and implementing sustainable practices such as replacing coal boilers with natural gas [27][28] - The company has received recognition for its ESG efforts, highlighting its commitment to environmental, social, and governance standards [30] Future Opportunities - The upcoming "15th Five-Year Plan" presents multiple opportunities for Jia Bi You, including favorable policies for biomanufacturing and increased demand for infant nutrition products [33][34] - The company believes that its internal capabilities and technological advancements will be the primary drivers of growth, rather than external trends [35]

Core Insights - Deloitte's report indicates a steady growth in the number of IPOs and financing amounts in the A-share market for 2026, with an expected 114 companies going public and raising 129.6 billion yuan [1] - The Hong Kong IPO market is projected to see around 160 new listings in 2026, with total financing expected to exceed 300 billion HKD [2] A-Share Market Summary - In 2025, the A-share market is expected to have 114 new listings, raising a total of 129.6 billion yuan, which represents a 14% increase in the number of IPOs and a 94% increase in financing compared to 2024 [1] - The top five IPOs in 2025 are projected to raise a total of 39.4 billion yuan, a significant increase of 260% from the previous year's 10.9 billion yuan [1] - Companies in priority sectors such as AI, new energy, high-end manufacturing, commercial aerospace, quantum technology, and biomanufacturing are expected to have a competitive advantage in the A-share market [1] Hong Kong Market Summary - For 2025, Hong Kong is anticipated to have 114 new IPOs, raising approximately 286.3 billion HKD, marking a 63% increase in the number of IPOs and a 227% increase in financing compared to the previous year [1] - The Hong Kong Stock Exchange is expected to lead global exchanges in total IPO financing for 2025 [1] - In 2026, the Hong Kong market is projected to have around 160 new listings, with at least 7 of them expected to raise over 10 billion HKD each, including leading mainland enterprises [2] - The focus will also be on "A+H" stock applicants, as well as sectors like technology, media, telecommunications, healthcare, consumer goods, and international companies [2]

手术机器人是本届展会关注的焦点之一，其发展已从单点突破走向多术式、全流程覆盖。如今，手术机 器人不仅仅作为解决单一术式的"工具"，更演进为覆盖多科室、整合多模式的智能手术平台，引领着手 术领域的革命性变革。 展会现场，精锋医疗展示了其单孔/多孔腔镜手术机器人，系统凭借灵活的"内腕"器械与高清三维视 觉，使单一切口下的复杂手术成为可能，大幅降低患者创伤；元化智能带来的髋膝单髁三位一体手术机 器人，将关节置换手术的规划、导航与执行融为一体，实现了对髋、膝关节疾病的全覆盖精准治疗；罗 伯医疗则专注于消化内镜赛道，其一次性使用柔性机械臂与主机系统配合，实现了内镜手术的精准操控 与全程无菌，正改变着传统内镜诊疗模式。 除了手术室里的"机械臂"，展会上能"读懂"人体信号的脑机接口产品，也引得无数观众驻足，成为另一 大亮点。脑机接口技术正突破传统医疗边界，从功能替代延伸到健康增强与主动干预，成为引领智慧医 疗未来的关键驱动力。 手术刀被机械臂精准替代，影像设备拥有"超清透视"之力，脑机接口正学习"翻译"神经信号，抗肿瘤药 带来颠覆性"新解"、玩游戏协助关节康复训练……这些勾勒未来医疗的想象，正生动地铺陈在2025深圳 国际 ...